Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1380)	5/30/2001 12:00:48 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1477

<<I agree that NG may not be the universal standard of care, but it was what the FDA asked SCIO to compare with Natrecor.>> Peter, At previous AC meeting MDs (AC panelists) main reason (in addition to N safety concern) for pissing on Natrecor was NTG golden efficacy. VMAC trial throw shit on their face, because NTG didn't do better than placebo. NTG comparison was MD-expert recommendation. Robert's position is just echo from first AC panelist. Miljenko